Pluristem Therapeutics Inc. Announces Pricing of Registered Direct Offering of Common Stock and Warrants

June 25, 2015 – HAIFA, Israel, — Pluristem Therapeutics Inc. (NASDAQCM:PSTI, TASE:PSTI) today announced that it has entered into definitive agreements to sell 6,800,000 shares of common stock and warrants to purchase up to 4,080,000 shares of common stock at a combined price of $2.50 per share and related warrants. The gross proceeds from the offering are expected to be approximately $17.0 million. The warrants have an exercise price of $2.85 per share of common stock, are immediately exercisable and expire 5 years from the closing of this offering.

Maxim Group acted as a sole placement agent to Pluristem’s $17.0 million registered direct.

This entry was posted in Investment Banking News: Q2- 2015. Bookmark the permalink.